GUIDED THERAPEUTICS INC (GTHP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 250K 500K 750K Q4 '15: 9K Q3 '16: 95K Q1 '17: 21K Q2 '17: 87K Q3 '17: 33K Q4 '17: 107K Q1 '18: 4K Q2 '18: 8K Q3 '18: 2K Q4 '18: 42K Q1 '19: 18K Q2 '19: 1K Q3 '19: 1K Q4 '19: 16K Q1 '20: 0 Q2 '20: 0 Q3 '20: 77K Q4 '20: 25K Q1 '21: 0 Q2 '21: 2K Q3 '21: 19K Q4 '21: 60K Q1 '22: 5K Q2 '22: 5K Q3 '22: 3K Q4 '22: 0 Q1 '23: 22K Q2 '23: 44K Q3 '23: 0 Q4 '23: 32K Q1 '24: 6K Q2 '24: 0 Q3 '24: 0 Q4 '24: 1K Q1 '25: 0 Q2 '25: 117K Q3 '25: 60K Q4 '25: 590K Q1 '26: 0 Q2 '26: 0 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-400K -200K 0 200K 400K 600K Q2 '16: 96K Q3 '16: 10K Q1 '17: 5K Q2 '17: 5K Q3 '17: -64K Q4 '17: -228K Q1 '18: 1K Q2 '18: 7K Q3 '18: 2K Q4 '18: -44K Q1 '19: 17K Q2 '19: -64K Q3 '19: 1K Q4 '19: 12K Q1 '20: 0 Q2 '20: -6K Q3 '20: 65K Q4 '20: 85K Q1 '21: 0 Q2 '21: 2K Q3 '21: -23K Q4 '21: 41K Q1 '22: 4K Q2 '22: 4K Q3 '22: 3K Q4 '22: -79K Q1 '23: 13K Q2 '23: 11K Q3 '23: -4K Q4 '23: 16K Q1 '24: 4K Q2 '24: 0 Q3 '24: 0 Q4 '24: -2K Q1 '25: 0 Q2 '25: 79K Q3 '25: 35K Q4 '25: 458K Q1 '26: 0 Q2 '26: 0 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q3 '16: -679K Q4 '16: -1.1M Q1 '17: -514K Q2 '17: -533K Q3 '17: -1.3M Q4 '17: -731K Q1 '18: -376K Q2 '18: -491K Q3 '18: -234K Q4 '18: -449K Q1 '19: -257K Q2 '19: -327K Q3 '19: -188K Q4 '19: -165K Q1 '20: -242K Q2 '20: -369K Q3 '20: -153K Q4 '20: -288K Q1 '21: -823K Q2 '21: -561K Q3 '21: -487K Q4 '21: -435K Q1 '22: -443K Q2 '22: -717K Q3 '22: -1.2M Q4 '22: -948K Q1 '23: -843K Q2 '23: -1.5M Q3 '23: -623K Q4 '23: -485K Q1 '24: -359K Q2 '24: -655K Q3 '24: -561K Q4 '24: -534K Q1 '25: -414K Q2 '25: -763K Q3 '25: -485K Q4 '25: -710K Q1 '26: -302K Q2 '26: -478K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-9M -6M -3M 0 3M 6M 9M Q2 '16: -1.9M Q3 '16: -211K Q4 '16: -2M Q1 '17: -107K Q2 '17: -1.1M Q3 '17: -2.4M Q4 '17: -8.7M Q1 '18: 1.1M Q2 '18: 3.4M Q3 '18: -746K Q4 '18: -2.7M Q1 '19: -215K Q2 '19: -2.7M Q3 '19: -126K Q1 '20: 2.7M Q2 '20: -6.8M Q3 '20: 1.6M Q4 '20: 2.2M Q1 '21: -517K Q2 '21: -1M Q3 '21: 68K Q4 '21: -444K Q1 '22: -507K Q2 '22: -926K Q3 '22: -1.1M Q4 '22: -1.8M Q1 '23: -869K Q2 '23: -1.6M Q3 '23: -677K Q4 '23: -386K Q1 '24: -402 Q2 '24: -709K Q3 '24: -654K Q4 '24: -652K Q1 '25: -427K Q2 '25: -811K Q3 '25: -742K Q4 '25: -1.2M Q1 '26: -500K Q2 '26: -605K Q2 '17 Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

-150K 0 150K 300K 450K Q1 '17: 16K Q2 '17: 82K Q3 '17: 97K Q4 '17: 335K Q1 '18: 3K Q2 '18: 1K Q3 '18: 0 Q4 '18: 86K Q1 '19: 1K Q2 '19: 65K Q3 '19: 0 Q4 '19: 4K Q1 '20: 0 Q2 '20: 6K Q3 '20: 12K Q4 '20: -60K Q1 '21: 0 Q2 '21: 0 Q3 '21: 42K Q4 '21: 19K Q1 '22: 1K Q2 '22: 1K Q3 '22: 0 Q4 '22: 79K Q1 '23: 9K Q2 '23: 33K Q3 '23: 4K Q4 '23: 16K Q1 '24: 2K Q2 '24: 0 Q3 '24: 0 Q4 '24: 3K Q1 '25: 0 Q2 '25: 38K Q3 '25: 25K Q4 '25: 132K Q1 '26: 0 Q2 '26: 0 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-900K -600K -300K 0 300K 600K 900K Q4 '16: -197K Q1 '17: -407K Q2 '17: 130K Q3 '17: -204K Q4 '17: -663K Q1 '18: -395K Q2 '18: -242K Q3 '18: -417K Q4 '18: -311K Q1 '19: -186K Q2 '19: -188K Q3 '19: -228K Q4 '19: -204K Q1 '20: -530K Q2 '20: -408K Q3 '20: -606K Q4 '20: -331K Q1 '21: -320K Q2 '21: -692K Q3 '21: -739K Q4 '21: 159K Q1 '22: -179K Q2 '22: -349K Q3 '22: -612K Q4 '22: -339K Q1 '23: -499K Q2 '23: -438K Q3 '23: -473K Q4 '23: -336K Q1 '24: -100K Q2 '24: -214K Q3 '24: -473K Q4 '24: -332K Q1 '25: -331K Q2 '25: -169K Q3 '25: -277K Q4 '25: -291K Q1 '26: -617K Q2 '26: -319K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-900K -600K -300K 0 300K 600K 900K Q3 '19: -228K Q4 '19: -204K Q1 '20: -530K Q2 '20: -409K Q3 '20: -606K Q4 '20: -331K Q1 '21: -321K Q2 '21: -696K Q3 '21: -744K Q4 '21: 155K Q1 '22: -193K Q2 '22: -366K Q3 '22: -615K Q4 '22: -342K Q1 '23: -499K Q2 '23: -438K Q3 '23: -473K Q4 '23: -336K Q4 '24: -332K Q4 '25: -291K Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '13: 65.7K Q3 '13: 66.3K Q1 '14: 71.5K Q2 '14: 73K Q3 '14: 77.7K Q1 '15: 973 Q2 '15: 107.3K Q3 '15: 2 Q1 '16: 109.9K Q2 '16: 41 Q3 '16: 283 Q1 '17: 946 Q2 '17: 1.9K Q3 '17: 6.9K Q1 '18: 2.5K Q2 '18: 2.7K Q3 '18: 394 Q1 '19: 3.2K Q2 '19: 3.3K Q3 '19: 3.3K Q1 '20: 65.6K Q2 '20: 11.9K Q3 '20: 60.3K Q1 '21: 13.2M Q2 '21: 13.3M Q3 '21: 13.4M Q1 '22: 20.7M Q2 '22: 26.3M Q3 '22: 34.8M Q1 '23: 49.3K Q2 '23: 51M Q3 '23: 51.5M Q1 '24: 54.8M Q2 '24: 56M Q3 '24: 57M Q1 '25: 68.3M Q2 '25: 78.8M Q3 '25: 81.7M Q1 '26: 88.8M Q2 '26: 96.5M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.21 -0.14 -0.07 0.00 0.07 0.14 0.21 Q4 '21: -0.17 Q1 '22: -0.18 Q2 '22: -0.13 Q3 '22: -0.16 Q4 '22: -0.16 Q1 '25: -0.05 Q2 '25: -0.05 Q3 '25: -0.05 Q4 '25: -0.04 Q1 '26: -0.04 Q2 '26: -0.04 Q4 '21 Q2 '22 Q4 '22 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.